Update on HIV-associated nephropathy

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 4, 2006, Pages 450-455

  Shah, Sonal Navin ^a   He, Cijiang John ^a   Klotman, Paul ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

HIV associated nephropathy; Mitogen activated protein kinase; Nef; Podocyte injury; Signal transducer and activator of transcription 3; Src kinase

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1;

CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE ASSOCIATION; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSGENE;

AIDS-ASSOCIATED NEPHROPATHY; ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE PRODUCTS, NEF; HIV-1; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PODOCYTES; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR; TRANSGENES;

EID: 33748054762     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000232887.58271.67     Document Type: Review

References (55)

1. US Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003.
2. Cantor ES, Kimmel PL, Bosch JP. Effect of race on expression of acquired immunodeficiency syndrome-associated nephropathy. Arch Intern Med 1991; 151:125-128.
3. Carbone L, D'Agati V, Cheng JT, Appel GB. Course and prognosis of human immunodeficiency virus-associated nephropathy. Am J Med 1989; 87:389-395.
4. Winston JA, Klotman ME, Klotman PE. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 1999; 55:1036-1040.
5. Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310:669-673.
6. Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344:1979-1984.
7. Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16:2412-2420.
8. Selik RM, Byers RH, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV-infected patients. J Acqir Immune Def Syndr 2003; 32:203-209.
9. D'Agati V, Suh JI, Carbone L, et al. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int 1989; 35:1358-1370.
10. Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11:2079-2087.
11. Bruggeman LA, Dikman S, Meng C, et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997; 100:84-92.
12. Zhong J, Zuo Y, Fogo A, et al. Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int 2005; 68:1048-1060. Details the findings that podocyte-specific expression of HIV-1 in a murine model is sufficient for the development of collapsing glomerulopathy. Pivotal study which establishes that infection of podocytes is essential for inducing the HIVAN phenotype.
13. Barisoni L, Bruggeman LA, Mundel P, et al. HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int 2000; 58:173-181.
14. Nelson PJ, Sunamoto M, Husain M, Gelman IH. HIV-1 expression induces cyclin D1 expression and Prb phosphorylation in infected podocytes: cell-cycle mechanisms contributing to the proliferative phenotype in HIV associated nephropathy. BMC Microbiol 2002; 2:26.
15. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10:51-61.
16. Shankland SJ, Eitner F, Hudkins KL, et al. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000; 58:674-683.
17. Gherardi D, D'Agati V, Chu T, et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 2004; 15:1212-1222.
18. Sunamoto M, Husain M, He JC, et al. Critical role for Nef in HIV dedifferentiation. Kidney Int 2003; 64:1695-1701.
19. Schwartz EJ, Cara A, Snoeck H, et al. Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. J Am Soc Nephrol 2001; 12:1677-1684.
20. Piguet V, Schwartz O, Le Gall S, Trono D. The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell receptors. Immunol Rev 1999; 168:51-63.
21. Skowronski J, Greenberg ME, Lock M, et al. HIV and SIV Nef modulate signal transduction and protein sorting in T cells. Cold Spring Harbor Symp Quant Biol 1999; 64:453-463.
22. Husain M, Gusella GL, Klotman ME, et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 2002; 13:1806-1815.
23. Hanna Z, Kay DG, Rebai N, et al. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998; 95:163-175.
24. Kajiyama W, Kopp JB, Marinos NJ, et al. Glomerulosclerosis and viral gene expression in HIV-transgenic mice: role of nef. Kidney Int 2000; 58:1148-1159.
25. Husain M, D'Agati VD, He JC, et al. HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. AIDS 2005; 19:1975-1980. Describes a murine model of podocyte-specific expression of nef. The findings suggest that nef expression is sufficient to induce podocyte de-differentiation, expression of proliferation markers, and activation of signaling pathways leading to cell proliferation. Provides compelling in-vivo evidence that nef alters podocyte phenotype and is essential for causing the early molecular changes which characterize HIVAN.
26. Geyer M, Fackler OT, Peterlin BM. Structure-function relationships in HIV-1 nef. EMBO Rep 2001; 2:580-585.
27. Lee CH, Saksela K, Mirza U, et al. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 1996; 85:931-942.
28. Hiipakka M, Huotari P, Manninen A, et al. Inhibition of cellular functions of HIV-1 Nef by artificial SH3 domains. Virology 2001; 286:152-159.
29. Arold ST, Bauer AS. Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein. Trends Biochem Sci 2001; 26:356-363.
30. Piguet V, Gu F, Foti M, et al. Nef-induced CD4 degradation: a diacidic-based motif in nef functions as a lysosomal targeting signal through the binding of β-COP in endosomes. Cell 1999; 97:63-73.
31. Schwartz O, Marechal V, Le Gall S, et al. Endocytosis of major histocompatibility complex class I molecules is induced by HIV-1 nef protein. Nat Med 1996; 2:338-342.
32. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001; 2:467-475.
33. Verma R, Wharram B, Kovari I, et al. Fyn binds to and phosphorylates the kidney slit diaphragm component Nephrin. J Biol Chem 2003; 278:20716-20723.
34. Lahdenpera J, Kilpelainen P, Liu XL, et al. Clustering-induced tyrosine phosphorylation of nephrin by Src family kinases. Kidney Int 2003; 64:404-413.
35. Akira S. Roles of STAT3 defined by tissue-specific gene. Oncogene 2000; 19:2607-2611.
36. Horiguchi A, Oya M, Marumo K, Murai M. Stat3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 2002; 61:926-938.
37. Barasch J, Yang J, Ware CB, et al. Mesenchymal to epithelial conversion in rat metanephros is induced by LIF. Cell 1999; 99:377-386.
38. Odajima J, Matsumura I, Sonoyama J, et al. Full oncogenic activities of v-Src are mediated by multiple signaling pathways. J Biol Chem 2000; 275:24096-24105.
39. Tian W, Zhang Z, Cohen DM. MAPK signaling and the kidney. Am J Physiol Renal Physiol 2000; 279:F593-F604.
40. Bokemeyer D, Guglielmi KE, McGinty A, et al. Activation of extracellular signal-regulated kinase in proliferative glomerulonephritis in rats. J Clin Invest 1997; 100:582-588.
41. Yang CW, Ahn HJ, Jung JY, et al. Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemic/reperfusion injury. Transplantation 2003; 75:20-24.
42. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995; 55:4182-4187.
43. Nagao S, Yamaguchi T, Kusaka M, et al. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int 2003; 63:427-437.
44. He JC, Husain M, Sunamoto M, et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 2004; 114:643-651.
45. Hanna Z, Weng X, Kay DG, et al. The pathogenicity of human immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is abolished by mutation of its SH3-binding domain, and disease development is delayed in the absence of Hck. J Virol 2001; 75:9378-9392.
46. Vincent P, Priceputu E, Kay D, et al. Activation of PAK2 and its association with nef are conserved in murine cells, but are not sufficient to induce an AIDS-like disease in CD4C/HIV transgenic mice. J Biol Chem 2006; 281:6940-6954. Suggests a possible role for the interaction and activation of human p21-activated kinase 2 (PAK2) by nef which leads to AIDS-like disease in several target organs in transgenic mice. Identifies another possible signaling mechanism through which nef may exert its pathogenic effects in the kidney.
47. Sells MA, Boyd JT, Chernoff J. p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol 1999; 145:837-849.
48. Rudel T, Zenke FT, Chuang TK, Bokoch GM. p21-activated kinase (PAK) is required for Fas-induced JNK activation in Jurkat cells. J Immunol 1998; 160:7-11.
49. Bagrodia S, Derijard B, Davis RJ, Cerione RA. Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J Biol Chem 1997; 270:27995-27998.
50. Rudel T, Bokoch GM. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 1997; 1276:1571-1574.
51. Jakobi R, Moertl E, Koeppel MA. p21-activated protein kinase gamma-PAK suppresses programmed cell death of BALB3T3 fibroblasts. J Biol Chem 2001; 276:16624-16634.
52. Schurmann A, Mooney AF, Sanders LC, et al. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol 2000; 20:453-461.
53. Wiskerchen M, Cheng-Mayer C. HIV-1 Nef association with cellular serine kinase correlates with enhanced virion infectivity and efficient proviral DNA synthesis. Virology 1996; 224:292-301.
54. Renkema GH, Manninen A, Mann DA, et al. Identification of the Nefassociated kinase as p21-activated kinase 2. Curr Biol 1999; 9:1407-1410.
55. Arora VK, Molina RP, Foster JL, et al. Lentivirus Nef specifically activates Pak2. Virology 2000; 74:11081-11087.